Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Blueprint Medicines to Present at Upcoming Investor Conferences in August
-
Blueprint Medicines (BPMC) PT Raised to $105 at Canaccord Genuity
-
Blueprint Medicines (BPMC) PT Raised to $96 at Canaccord Genuity; 'Catalyst-rich 2018; data flow from all programs'
-
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
-
Blueprint Medicines (BPMC) Prices 3.7M Share Offering at $81/Sh
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) to Offer $275M in Common Stock
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC): Raising Estimates After Harvard KOL Discussion - Canaccord
-
Blueprint Medicines to Present at Upcoming Investor Conferences in August
-
Blueprint Medicines (BPMC) PT Raised to $42 at Canaccord Genuity Following BLU-285 Highlights at AACR Conference
-
Canaccord Genuity Starts Blueprint Medicines (BPMC) at Buy
-
Blueprint Medicines to Present at Upcoming Investor Conferences in August

